QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID
Phase 2/3Active 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Netherton Syndrome
Conditions
Netherton Syndrome
Trial Timeline
Jun 23, 2022 → Dec 31, 2026
NCT ID
NCT05521438About QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID
QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID is a phase 2/3 stage product being developed by Quoin Pharmaceuticals for Netherton Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05521438. Target conditions include Netherton Syndrome.
Hype Score Breakdown
Clinical
15
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05521438 | Phase 2/3 | Active |
Competing Products
8 competing products in Netherton Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-2325a | Daiichi Sankyo | Phase 1/2 | 24 |
| DS-2325a + DS-2325a + Placebo + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-2325a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| Pimecrolimus 1% Cream | Novartis | Phase 1/2 | 32 |
| BCX17725 + Placebo | BioCryst Pharmaceuticals | Phase 1 | 30 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| ATR12-351 | Azitra | Phase 1 | 26 |